CSF biomarkers for mild cognitive impairment and early Alzheimer's disease
- 30 April 2005
- journal article
- review article
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 107 (3), 165-173
- https://doi.org/10.1016/j.clineuro.2004.10.011
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Differentiation of Geriatric Major Depression From Alzheimer’s Disease With CSF Tau Protein Phosphorylated at Threonine 231American Journal of Psychiatry, 2003
- Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsyMovement Disorders, 2002
- Cerebrospinal Fluid Amyloid β1–42 Levels in the Mild Cognitive Impairment Stage of Alzheimer's DiseaseExperimental Neurology, 2001
- Age-Dependent Change in the Levels of Aβ40 and Aβ42 in Cerebrospinal Fluid from Control Subjects, and a Decrease in the Ratio of Aβ42 to Aβ40 Level in Cerebrospinal Fluid from Alzheimer’s Disease PatientsEuropean Neurology, 2000
- Tau and apo E in CSFNeuroReport, 1999
- Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 alleleJournal of Neural Transmission, 1996
- Tau protein and the neurofibrillary pathology of Alzheimer's diseaseTrends in Neurosciences, 1993
- Microtubule formation and neurite growth in cerebellar macroneurons which develop in vitro: evidence for the involvement of the microtubule-associated proteins, MAP-1a, HMW-MAP2 and TauDevelopmental Brain Research, 1989
- The prevalence of dementia: A quantitative integration of the literatureActa Psychiatrica Scandinavica, 1987
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984